ANALIZE MEDICALE DE LABORATOR
            Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
            Selectati o categorie din lista de mai jos:
            
         
     
    
    
    
        Solutie antistress!
 Construieste poduri :)
        
        
        Prinde pisica neagra :)
        
     
 
Osteotech Receives FDA Clearance For First Product Under Its Plexus Technology Platform
Osteotech, Inc. 
(Nasdaq: OSTE) announced today that the Food and Drug Administration 
("FDA") has cleared its 510(k) submission for an osteoconductive, 
bone/polymer biocomposite, which will be the first commercial product 
manufactured under Osteotech's proprietary Plexus Technology Platform. This 
new product, which will be marketed under the trade name Plexur(TM) P, is a 
porous, resorbable scaffold that can be used to fill bony voids of the 
pelvis and extremities.
 
 
Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, 
stated, "We are very pleased to be able to introduce the Plexur(TM) P. Our 
internal team has done an excellent job developing this product and with 
this approval we expect to introduce additional products utilizing the 
Plexus Technology in the future."
 
    
Plexur(TM) P is an osteoconductive biocomposite of cortical mineralized 
bone fibers suspended in a resorbable porous polymer scaffold that has 
demonstrated controlled remodeling and resorption characteristics. 
Plexur(TM) P incorporates overlapping bone fibers with interconnected 
pores, which simulate bone structure, facilitate absorption of blood and 
allowing multiple pathways for bone forming cells to begin the remodeling 
process. Plexur(TM) P will initially be available as granules and 
cylindrical plugs, but ultimately, will be available in multiple forms 
including blocks, wedges and sheets. Plexur(TM) P uses proprietary 
processing steps that have been shown to inactivate viruses. Plexur(TM) P 
is also terminally sterilized.
 
    
Mr. Owusu-Akyaw concluded, "Plexur(TM) P will be officially introduced  
at the American Academy of Orthopedic Surgeons 2007 Annual Meeting, 
February 14 through 16, 2007, in San Diego, California. Plexur(TM) P will 
be positioned to compete against osteoconductive synthetic bone void 
fillers. We expect to begin distributing Plexur(TM) P in March 2007 at key 
centers of excellence to allow for the gathering of human clinical 
information before a worldwide launch of the product in the third quarter 
of 2007. This is in line with our strategy to use science to market 
osteo-biologic products."
 
    
The Plexus Technology is designed to utilize bone tissue for procedure- 
specific surgical applications in combination with a wide variety of  
polymers. On a worldwide basis, Osteotech controls over 17 patents and over 
68 pending patent applications covering the Plexus Technology for human and 
xenograft bone tissue.
 
    
Certain statements made throughout this press release that are not 
historical facts contain forward-looking statements (as such are defined in 
the Private Securities Litigation Reform Act of 1995) regarding the 
Company's future plans, objectives and expected performance. Any such 
forward-looking statements are based on assumptions that the Company 
believes are reasonable, but are subject to a wide range of risks and 
uncertainties and, therefore, there can be no assurance that actual results 
may not differ materially from those expressed or implied by such 
forward-looking statements. Factors that could cause actual results to  
differ materially include, but are not limited to, the inability to obtain 
required regulatory approvals for products on a timely basis or at all, 
differences in anticipated and actual product and service introduction 
dates, the ultimate success of those products in the market place, the 
continued acceptance and growth of current products and services, the 
impact of competitive products and services, the availability of sufficient 
quantities of suitable donated tissue and the success of cost control and  
margin improvement efforts. Certain of these factors are detailed from time 
to time in the Company's periodic reports filed with the Securities and 
Exchange Commission. All information in this press release is as of 
February 8, 2007 and the Company undertakes no duty to update this 
information.
 
    
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a leading 
provider of human bone and bone connective tissue for transplantation and  
an innovator in the development and marketing of biomaterial and implant 
products for musculoskeletal surgery. For further information regarding 
Osteotech or this press release, please go to Osteotech's website at 
http://www.osteotech.com.
 
Osteotech, Inc.
http://www.osteotech.com
		
Osteotech primeºte FDA Clearance-ul pentru prima sa produs în cadrul platformei tehnologie plex - Osteotech Receives FDA Clearance For First Product Under Its Plexus Technology Platform - articole medicale engleza - startsanatate